Medical Program: Locally advanced prostate cancer, muscle-invasive bladder cancer

Be part of the knowledge.™

Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer

Media formats available:

Details

Comments

Overview
SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette-Guérin in patients with Bacillus Calmette-Guérin-naive high-risk non–muscle-invasive bladder cancer.
Advancements in genitourinary cancers are evolving rapidly, and it is often challenging for busy urologists and urologic oncologists to stay current with these emerging data, which can lead to suboptimal outcomes in their patients. In this activity, expert faculty assess key data in locally advanced prostate cancer and bladder cancer and best practices for the integration of these findings to clinical practice.

Recommended

Details

Comments

Overview
SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette-Guérin in patients with Bacillus Calmette-Guérin-naive high-risk non–muscle-invasive bladder cancer.
Advancements in genitourinary cancers are evolving rapidly, and it is often challenging for busy urologists and urologic oncologists to stay current with these emerging data, which can lead to suboptimal outcomes in their patients. In this activity, expert faculty assess key data in locally advanced prostate cancer and bladder cancer and best practices for the integration of these findings to clinical practice.